BOOK
Bariatric and Metabolic Endoscopy, An Issue of Gastrointestinal Endoscopy Clinics, E-Book
(2017)
Additional Information
Book Details
Abstract
Dr. Rothstein has assembled top experts to present the current status of the role of endoscopy in managing the obese patient. Authors present current clinical information on the following topics: Small Bowel Target Devices and Techniques; Reimbursement Issues for Endoscopic Devices Used for Metabolic Endoscopy; the Physiologic Alteractions of Bariatric Surgery; Non-Balloon Gastric and Pyloric Therapies for Obesity; Aspiration Therapy for Obesity; Endoscopic Therapies after Surgery; Duodenal Mucosal Resurfacing: Role for Diabetes Treatment; Gastric Plication; and Gastric Balloons. Readers should come away with the information they need to utilize endoscopic techniques to improve outcomes in their patients.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Bariatric and MetabolicEndoscopy | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITOR | iii | ||
| EDITOR | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Foreword: Bariatric and Metabolic Endoscopy: New Approaches to Obesity and Diabetes | vii | ||
| Preface: Bariatric and Metabolic Endoscopy | vii | ||
| Current and Future Medical Treatment of Obesity | vii | ||
| Surgical Treatment of Obesity and Diabetes | vii | ||
| What Bariatric Surgery Can Teach Us About Endoluminal Treatment of Obesity and Metabolic Disorders | vii | ||
| Endoscopic Treatments Following Bariatric Surgery | viii | ||
| Intragastric Balloons in Clinical Practice | viii | ||
| Gastric Plication | viii | ||
| Selected Endoscopic Gastric Devices for Obesity | viii | ||
| Aspiration Therapy for Obesity | ix | ||
| Small Bowel Target Devices and Techniques | ix | ||
| Hydrothermal Duodenal Mucosal Resurfacing: Role in the Treatment of Metabolic Disease | ix | ||
| Therapeutic Options to Treat Pediatric Obesity | ix | ||
| The Regulatory Perspectives on Endoscopic Devices for Obesity | x | ||
| Reimbursement for Endoscopic Bariatric Therapies | x | ||
| GASTROINTESTINAL ENDOSCOPY CLINICS\rOF NORTH AMERICA\r | xi | ||
| FORTHCOMING ISSUES | xi | ||
| July 2017 | xi | ||
| October 2017 | xi | ||
| January 2018 | xi | ||
| RECENT ISSUES | xi | ||
| January 2017 | xi | ||
| October 2016 | xi | ||
| July 2016 | xi | ||
| Foreword: Bariatric and Metabolic Endoscopy: New Approaches to Obesity and Diabetes\r | xiii | ||
| Preface:\rBariatric and Metabolic Endoscopy | xv | ||
| Current and Future Medical Treatment of Obesity | 181 | ||
| Key points | 181 | ||
| INTRODUCTION | 181 | ||
| PHENTERMINE | 182 | ||
| ORLISTAT (XENICAL) | 183 | ||
| LORCASERIN (BELVIQ) | 183 | ||
| PHENTERMINE/TOPIRAMATE ER (QSYMIA) | 184 | ||
| LIRAGLUTIDE 3.0 (SAXENDA) | 184 | ||
| NALTREXONE ER/BUPROPION ER (CONTRAVE) | 185 | ||
| Antidiabetic Medications That Promote Weight Loss | 186 | ||
| Sodium glucose transporter 2 inhibitors | 186 | ||
| Glucagon-like Polypeptide-1 agonists | 187 | ||
| Pramlintide (Symlin) | 187 | ||
| Future Option for Obesity Pharmacotherapy | 188 | ||
| Gelesis 100 | 188 | ||
| SUMMARY | 188 | ||
| REFERENCES | 188 | ||
| Surgical Treatment of Obesity and Diabetes | 191 | ||
| Key points | 191 | ||
| INTRODUCTION | 191 | ||
| PATIENT SELECTION FOR METABOLIC SURGERY | 192 | ||
| TECHNIQUE OF THE PROCEDURES | 194 | ||
| Approach | 194 | ||
| Liver retraction | 194 | ||
| Operative Procedures | 195 | ||
| Sleeve gastrectomy | 195 | ||
| Adjustable gastric band | 196 | ||
| Roux-en-Y gastric bypass | 197 | ||
| Other Gastrojejunal Anastomosis Options | 197 | ||
| Gastric Pouch Ring Placement | 199 | ||
| Biliopancreatic diversion/duodenal switch | 200 | ||
| Complications and Management | 201 | ||
| POSTOPERATIVE CARE | 204 | ||
| OUTCOMES | 205 | ||
| Weight Loss | 205 | ||
| Type 2 Diabetes Remission and Improvement | 205 | ||
| Cardiovascular Risk Reduction | 207 | ||
| Current Controversies and Future Considerations | 207 | ||
| Cirrhosis improvement after metabolic surgery | 207 | ||
| Metabolic surgery in patients with diabetes and mild obesity (body mass index 30–34) | 208 | ||
| SUMMARY | 208 | ||
| REFERENCES | 209 | ||
| What Bariatric Surgery Can Teach Us About Endoluminal Treatment of Obesity and Metabolic Disorders | 213 | ||
| Key points | 213 | ||
| INTRODUCTION | 213 | ||
| REGULATION OF ENERGY BALANCE | 215 | ||
| WHAT CAUSES OBESITY? | 216 | ||
| BARIATRIC SURGICAL PROCEDURES | 217 | ||
| Roux-en-Y Gastric Bypass | 217 | ||
| Biliopancreatic Diversion | 218 | ||
| Vertical Sleeve Gastrectomy | 219 | ||
| Adjustable Gastric Banding | 219 | ||
| MECHANISMS OF WEIGHT LOSS AFTER BARIATRIC SURGERY | 219 | ||
| ANATOMIC DETERMINANTS OF RESPONSE | 220 | ||
| EFFECT OF SURGERY ON METABOLIC DISEASES | 221 | ||
| PHYSIOLOGIC MECHANISMS OF SURGICAL ACTION | 223 | ||
| Appetitive Drives and Appetite-Regulating Hormones | 223 | ||
| Energy Expenditure | 224 | ||
| Regulation of Circadian Rhythms | 224 | ||
| Bile Acids | 225 | ||
| Microbiota | 225 | ||
| Integrated Responses to Bariatric Surgery | 226 | ||
| IMPLICATIONS FOR ENDOSCOPIC TREATMENT OF OBESITY AND RELATED METABOLIC DISORDERS | 226 | ||
| REFERENCES | 228 | ||
| Endoscopic Treatments Following Bariatric Surgery | 233 | ||
| Key points | 233 | ||
| INTRODUCTION | 233 | ||
| PATIENT EVALUATION FOR WEIGHT REGAIN AFTER BARIATRIC SURGERY | 234 | ||
| ENDOSCOPIC BARIATRIC REVISION PROCEDURES | 235 | ||
| Argon Plasma Coagulation | 235 | ||
| The Transoral Outlet Reduction and Purse String | 236 | ||
| Weight Regain after Sleeve Gastrectomy | 239 | ||
| ENDOSCOPIC MANAGEMENT OF OTHER COMPLICATIONS OF BARIATRIC SURGERY | 239 | ||
| Gastro-Gastric Fistula | 240 | ||
| Marginal Ulceration and Bleeding | 241 | ||
| SUMMARY/DISCUSSION | 242 | ||
| REFERENCES | 243 | ||
| Intragastric Balloons in Clinical Practice | 245 | ||
| Key points | 245 | ||
| INTRAGASTRIC BALLOONS | 246 | ||
| MECHANISM OF ACTION | 246 | ||
| TYPES OF INTRAGASTRIC BALLOONS APPROVED FOR USE IN THE UNITED STATES | 247 | ||
| WEIGHT LOSS AND METABOLIC OUTCOMES IN INTRAGASTRIC BALLOON TRIALS | 247 | ||
| ADVERSE EVENTS | 248 | ||
| INTRAGASTRIC BALLOONS IN CLINICAL PRACTICE | 250 | ||
| THE FUTURE OF INTRAGASTRIC BALLOONS | 254 | ||
| REFERENCES | 255 | ||
| Gastric Plication | 257 | ||
| Key points | 257 | ||
| INTRODUCTION | 257 | ||
| ENDOLUMINAL VERTICAL GASTROPLASTY | 258 | ||
| ENDOSCOPIC SLEEVE GASTROPLASTY | 258 | ||
| Superficial Thickness Suturing | 258 | ||
| Full-Thickness Suturing | 258 | ||
| Procedure Development | 259 | ||
| Procedure Technique | 260 | ||
| Clinical Results | 260 | ||
| Mechanism | 261 | ||
| OTHER GASTRIC RESTRICTIVE PROCEDURES | 261 | ||
| Primary Obesity Surgery Endolumenal | 261 | ||
| Transoral Gastroplasty | 262 | ||
| Articulating Endoscopic Circular Stapler | 262 | ||
| SUMMARY | 263 | ||
| REFERENCES | 264 | ||
| Selected Endoscopic Gastric Devices for Obesity | 267 | ||
| Key points | 267 | ||
| SELECTED STOMACH TARGET DEVICES | 268 | ||
| Introduction | 268 | ||
| Devices/Techniques Affecting Gastric Emptying | 268 | ||
| Gastric botulinum toxin A injection | 268 | ||
| Transpyloric shuttle | 269 | ||
| Devices/Techniques Affecting Gastric Wall or Postbypass Stomal Compliance | 270 | ||
| Endoscopic sclerotherapy | 270 | ||
| Endoscopic radiofrequency ablation | 271 | ||
| Gastric Volume Restriction Devices | 271 | ||
| Transoral endoscopic restrictive implant system device | 271 | ||
| Articulating circular endoscopic stapler | 272 | ||
| FullSense device | 272 | ||
| Gelesis100 hydrogel capsule | 273 | ||
| Magnetically weight loss capsule | 273 | ||
| SUMMARY | 274 | ||
| REFERENCES | 274 | ||
| Aspiration Therapy for Obesity | 277 | ||
| Key points | 277 | ||
| INTRODUCTION | 277 | ||
| ASPIRATION AND THE COMPONENTS OF THE ASPIREASSIST SYSTEM | 278 | ||
| Permanent Components | 278 | ||
| Components Only Attached During Aspiration | 278 | ||
| PATIENT EVALUATION OVERVIEW | 279 | ||
| OUTCOMES | 280 | ||
| Weight Loss | 280 | ||
| Cardiometabolic Risk Factors | 282 | ||
| Eating Behaviors | 282 | ||
| Psychological Evaluations | 283 | ||
| COMPLICATIONS | 283 | ||
| ELECTROLYTES | 285 | ||
| MECHANISMS OF ACTION FOR WEIGHT LOSS | 285 | ||
| SUMMARY | 286 | ||
| REFERENCES | 286 | ||
| Small Bowel Target Devices and Techniques | 289 | ||
| Key points | 289 | ||
| INTRODUCTION | 289 | ||
| ENDOLUMINAL SLEEVES | 290 | ||
| Duodenal Jejunal Bypass Liner | 290 | ||
| Gastroduodenojejunal Bypass Sleeve | 293 | ||
| DUAL-PATH ENTERAL BYPASS | 293 | ||
| DUODENAL MUCOSAL RESURFACING | 295 | ||
| SUMMARY | 295 | ||
| REFERENCES | 295 | ||
| Hydrothermal Duodenal Mucosal Resurfacing | 299 | ||
| Key points | 299 | ||
| INTRODUCTION | 300 | ||
| INSULIN-RESISTANT STATES: BACKGROUND AND CURRENT MANAGEMENT | 300 | ||
| Background | 300 | ||
| Lifestyle/Behavior Modification | 300 | ||
| Pharmacologic Treatment | 301 | ||
| Bariatric Surgery | 301 | ||
| METABOLIC ROLE OF THE DUODENUM | 302 | ||
| Evidence from Animal Models | 302 | ||
| Evidence from Humans | 303 | ||
| DUODENAL MUCOSAL RESURFACING: METHOD FOR CORRECTING DUODENAL METABOLIC SIGNALING | 303 | ||
| Rationale for Targeting Duodenal Mucosa | 303 | ||
| Targeting Duodenal Mucosa in Animal Models: Proof of Concept | 303 | ||
| Duodenal Mucosal Resurfacing Catheter (Revita) and Procedure | 305 | ||
| First-in-Human Study of Revita Duodenal Mucosal Resurfacing in Type 2 Diabetes | 305 | ||
| Safety Profile of Duodenal Mucosal Resurfacing in Early Human Use | 305 | ||
| Glycemic Improvement in Subjects with Type 2 Diabetes in the First-in-Human Study | 306 | ||
| Wider Metabolic Effects of Duodenal Mucosal Resurfacing Observed in Human Subjects | 307 | ||
| SUMMARY | 307 | ||
| REFERENCES | 308 | ||
| Therapeutic Options to Treat Pediatric Obesity | 313 | ||
| Key points | 313 | ||
| INTRODUCTION | 313 | ||
| GOALS OF THERAPY | 314 | ||
| DIET, ACTIVITY, AND BEHAVIOR: HEALTHY LIVING | 315 | ||
| BARIATRIC SURGICAL PROCEDURES | 317 | ||
| WEIGHT LOSS MEDICATIONS | 319 | ||
| WEIGHT LOSS DEVICES | 320 | ||
| ENDOSCOPIC WEIGHT LOSS PROCEDURES | 322 | ||
| OTHER TECHNIQUES | 323 | ||
| SUMMARY | 323 | ||
| REFERENCES | 324 | ||
| The Regulatory Perspectives on Endoscopic Devices for Obesity | 327 | ||
| Key points | 327 | ||
| INTRODUCTION | 327 | ||
| DISCUSSION | 329 | ||
| Regulatory Pathways for Obesity Devices | 329 | ||
| Premarket notification (510[k]) | 329 | ||
| The de novo classification process | 329 | ||
| The premarket approval process | 329 | ||
| Clinical Studies to Support Safety and Effectiveness of Obesity Treatment Devices | 330 | ||
| Nonclinical testing | 330 | ||
| Pediatric patients | 330 | ||
| Benefit-risk paradigm | 331 | ||
| Benefit-Risk of US Food and Drug Administration–Approved Endoscopic Weight-Loss Devices | 332 | ||
| ReShape intragastric balloon | 333 | ||
| ORBERA intragastric balloon | 333 | ||
| Obalon intragastric balloon (balloon system) | 334 | ||
| AspireAssist gastric emptying device | 335 | ||
| Patient-reported outcomes | 335 | ||
| Patient Preference for Endoscopic Weight-Loss Devices | 336 | ||
| Summary | 338 | ||
| ACKNOWLEDGMENTS | 338 | ||
| REFERENCES | 338 | ||
| Reimbursement for Endoscopic Bariatric Therapies | 343 | ||
| Key points | 343 | ||
| CODING ENDOSCOPIC PLACEMENT AND REMOVAL OF GASTRIC DEVICES FOR THE MANAGEMENT OF OBESITY | 344 | ||
| COMPLICATIONS RELATED TO GASTRIC DEVICES FOR THE MANAGEMENT OF OBESITY | 345 | ||
| DATA COLLECTION | 348 | ||
| INTERNATIONAL STATISTICAL CLASSIFICATION OF DISEASES AND RELATED HEALTH PROBLEMS, 10TH REVISION, CODES FOR OBESITY | 349 | ||
| SUMMARY | 350 | ||
| REFERENCES | 350 |